India-centric branded pharma maker of chronic-therapy formulations: cardio-diabetes, women's health, urology.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 61 | 61 | 61 | 61 | 61 |
| Reserves | 347 | 419 | 545 | 598 | 686 |
| Borrowings | 28 | 159 | 86 | 63 | 165 |
| Other Liabilities | 159 | 191 | 237 | 254 | 293 |
| Total Liabilities | 595 | 831 | 930 | 977 | 1.2k |
| AssetsFixed Assets | 185 | 384 | 370 | 394 | 554 |
| CWIP | 65 | 121 | 186 | 205 | 143 |
| Investments | 32 | 26 | 26 | 0 | 26 |
| Other Assets | 314 | 301 | 348 | 378 | 482 |
| Total Assets | 595 | 831 | 930 | 977 | 1.2k |
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ActivitiesCash from Operating | 103 | 157 | 190 | 229 |
| Cash from Investing | -50 | -267 | -84 | -256 |
| Cash from Financing | -45 | 99 | -107 | 25 |
| SummaryCapital Expenditure | — | — | — | — |
| Free Cash Flow | 9 | -129 | 99 | 56 |
| FCF Margin | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (50.4×) and current (69.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 50× exit, ₹2113 only delivers your return if you pay ₹1,049. The price is currently baking in 25% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 50×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 33.29 |
| FY28 | 10.0% | 36.61 |
| FY29 | 10.0% | 40.28 |
| FY30 | 10.0% | 44.30 |
| FY31 | 10.0% | 48.73 |
| FY32 | 8.0% ·fade | 52.63 |
| FY33 | 6.0% ·fade | 55.79 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.